CommercialCoverageMedium impact
Autoimmune Antibody and Coagulation Testing (CPB 0662, reviewed 2025-12-08)
Aetna·Hematology, Internal Medicine, OB-GYN +1 more·Medical Policy
Effective date
Dec 8, 2025
We identified it
Aug 12, 2026
Summary
Aetna's updated CPB 0662 (effective 2025-12-08) clarifies coverage for von Willebrand disease (VWD) diagnostic testing, designating specific collagen-binding and multimer analysis assays as medically necessary while classifying antiprothrombin antibody testing, heparin-induced thrombocytopenia testing, and VWF propeptide antigen assays as experimental/unproven and non-covered. Billing teams must immediately update claim submission logic to distinguish between covered CPT codes (0279U, 0280U, 0283U, 0284U) and non-covered codes (0275U, 0281U).
Action Required
By December 8, 2025: Billing team must immediately update claim submission rules in billing software to reflect Aetna's coverage determination. COVERED codes requiring appropriate ICD-10 diagnosis codes (D68.020, D68.021, D68.022, D68.023, D68.029, D68.09 for VWD types): CPT 0279U, 0280U, 0283U, 0284U. NON-COVERED codes (will be denied as experimental/investigational): CPT 0275U (HIT testing), 0281U (VWF propeptide), and antiprothrombin antibody testing. Update claim edits to automatically deny claims for 0275U and 0281U with reason code for experimental services. Ensure providers understand that ancillary coagulation codes (85300-85306, 86147, 86148, 86880) are related but require separate medical necessity review per the policy. Flag any claims submitted with non-covered VWD diagnosis codes (D68.61, N96, O26.20-O26.23) for manual review to ensure antiprothrombin or propeptide testing is not being billed. Failure to implement these edits will result in claim denials and overpayment recoupment.